P-SERS™ for Cancer Biomarker Detection featured in American Pharmaceutical Review
P-SERS™ substrates have been featured in an article published in the American Pharmaceutical Review entitled Raman Spectroscopy Could Facilitate Deployment of Amantadine-Based Cancer Screening Technology – Enabling the Transition from Labs to Villages”.
Our partners at Innovative Photonic Solutions and BioMark Diagnostics describe how the combination of functionalized P-SERS™ substrates with reader hardware from IPS has the potential to revolutionize BioMark’s early stage cancer screening test. Currently an expensive central lab test which costs hundreds of dollars, P-SERS™ has the potential to enable cancer screening to be performed in clinics in first and third-world countries for a tiny fraction of the cost of a central-lab test.
In partnership with BioMark Diagnostics, research efforts are currently underway at Diagnostic anSERS to develop a proof-of-concept functionalized P-SERS™ sensor to enable low-cost lung cancer screening. The underlying cancer screening test has been in development for nearly a decade and is currently undergoing clinical trials involving hundreds of patients.